LLY

1,084.65

+0.71%↑

JNJ

208.24

+0.36%↑

ABBV

230.83

+0.29%↑

UNH

329.56

-0.61%↓

AZN

92.71

-0.19%↓

LLY

1,084.65

+0.71%↑

JNJ

208.24

+0.36%↑

ABBV

230.83

+0.29%↑

UNH

329.56

-0.61%↓

AZN

92.71

-0.19%↓

LLY

1,084.65

+0.71%↑

JNJ

208.24

+0.36%↑

ABBV

230.83

+0.29%↑

UNH

329.56

-0.61%↓

AZN

92.71

-0.19%↓

LLY

1,084.65

+0.71%↑

JNJ

208.24

+0.36%↑

ABBV

230.83

+0.29%↑

UNH

329.56

-0.61%↓

AZN

92.71

-0.19%↓

LLY

1,084.65

+0.71%↑

JNJ

208.24

+0.36%↑

ABBV

230.83

+0.29%↑

UNH

329.56

-0.61%↓

AZN

92.71

-0.19%↓

Search

Sanofi

Abierto

48.37 -0.12

Resumen

Variación precio

24h

Actual

Mínimo

48.22

Máximo

48.63

Métricas clave

By Trading Economics

Ingresos

-1.1B

2.8B

Ventas

2.4B

13B

P/B

Media del Sector

15.645

78.892

BPA

1.689

Margen de beneficios

21.276

Empleados

82,878

EBITDA

2.3B

4.2B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+67.69% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-5.9B

117B

Apertura anterior

48.49

Cierre anterior

48.37

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Sanofi Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 dic 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

24 dic 2025, 11:17 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Dynavax Shares Leap Premarket on Takeover by Sanofi

24 dic 2025, 06:55 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

15 dic 2025, 10:11 UTC

Principales Movimientos del Mercado

Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback

24 oct 2025, 08:29 UTC

Ganancias

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24 oct 2025, 07:00 UTC

Ganancias

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

24 dic 2025, 17:08 UTC

Adquisiciones, fusiones, absorciones

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 12:59 UTC

Adquisiciones, fusiones, absorciones

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 06:41 UTC

Adquisiciones, fusiones, absorciones

Correct: Sanofi: Deal Expected to Have No Impact on 2025 Guidance

24 dic 2025, 06:19 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Acquisition to Close in 1Q of 2026

24 dic 2025, 06:19 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Deal Expected to Have on Impact on 2025 Guidance

24 dic 2025, 06:19 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Offering $15.50 a Share in Cash for Dynavax

24 dic 2025, 06:18 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Start Cash Tender Offer at Equity Value of $2.2B

24 dic 2025, 06:18 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Deal Adds Marketed Adult Hepatitis B Vaccine, Phase 1/2 Shingles Candidate

24 dic 2025, 06:17 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vaccine Company Dynavax Technologies

24 dic 2025, 06:16 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Dynavax

24 dic 2025, 06:15 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi To Acquire Dynavax, Adding A Marketed Adult Hepatitis B Vaccine And Phase 1/2 Shingles Candidate To The Pipeline >SAN.FR

15 dic 2025, 15:03 UTC

Charlas de Mercado

Sanofi Multiple Sclerosis Trial Failure Leaves FDA Approval in Doubt -- Market Talk

15 dic 2025, 13:59 UTC

Acciones populares

Stocks to Watch Monday: iRobot, Tilray, EchoStar, Juventus -- WSJ

15 dic 2025, 11:18 UTC

Charlas de Mercado

Sanofi's Multiple Sclerosis Drug Fails Late-Stage Trial; Latest Pipeline Setback -- Market Talk

15 dic 2025, 09:53 UTC

Acciones populares

Stocks to Watch Monday: iRobot, EchoStar, Rocket Lab, Alibaba -- WSJ

4 dic 2025, 10:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes Acquisition of Vicebio

4 dic 2025, 10:01 UTC

Adquisiciones, fusiones, absorciones

Sanofi Buys Vicebio

4 dic 2025, 10:00 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes Acquisition Of Vicebio >SAN.FR

24 oct 2025, 08:21 UTC

Charlas de Mercado
Ganancias

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 oct 2025, 07:56 UTC

Charlas de Mercado
Ganancias

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24 oct 2025, 05:30 UTC

Ganancias

Sanofi 3Q Adj EPS EUR2.91

24 oct 2025, 05:30 UTC

Ganancias

Sanofi Backs 2025 View

24 oct 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

24 oct 2025, 05:30 UTC

Ganancias

Sanofi 3Q Business Net Profit at EUR3.55B

Comparación entre iguales

Cambio de precio

Sanofi previsión

Precio Objetivo

By TipRanks

67.69% repunte

Estimación a 12 Meses

Media 81.28 USD  67.69%

Máximo 117.852 USD

Mínimo 57 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

51.665 / 52.38Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat